Save up -80% on Nivolumab
Note: this is a drug discount program, not an insurance plan.
Pharmacists and Patients support.
2018 Price of Opdivo
40mg/4ml
* price without discount in nearest pharmacy. Price may vary.
Claim your free Nivolumab discount card
We offer free Nivolumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Nivolumab every time. What are you waiting for? Claim your prescription drug card now!
Nivolumab volume of distribution
8.0 L
About RX24Drugs
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Nivolumab
Nivolumab is a fully human IgG4 monoclonal antibody that acts as an immunomodulator by blocking ligand activation of programmed cell death 1 (PD-1) receptor on T cells. It is indicated for use in patients with unresectable (cannot be surgically removed) or metastatic melanoma who no longer respond to other drugs. Nivolumab is administered as an intravenous infusion over 60 minutes every 2 weeks.
Nivolumab mechanism of action
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models.
Dosage forms of Nivolumab
| Drug | Dosage | Quantity | Price |
|---|---|---|---|
| Opdivo | 40mg/4ml | 1 vial | $1,068 |
| Opdivo | 100mg/10ml | 1 vial | $2,612 |
Prescription Generics
false
International Brands
Opdivo
Synonyms
Manufacturers
E.R. Squibb – Sons, L.L.C.
CAS number
946414-94-4
UNII
31YO63LBSN
State
solid
Affected organisms
Indication of Nivolumab
Nivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access.
Toxicity of Nivolumab
Based on data from animal studies, there is risk of fetal harm when administered to pregnant women. It is therefore advisable for pregnant women to use contraception during treatment and for 5 months afterwards. There have been reported cases of severe pneumonitis or interstitial lung disease, including fatal cases, with the use of nivolumab during clinical trials. Therefore, patients taking this drug should be monitored for signs and symptoms of pneumonitis. During clinical trials there have also been reports of the development of immune-mediated colitis, immune-mediated hepatitis with increased liver test abnormalities, immune-mediated nephritis and renal dysfunction, immune-mediated hypothyroidism and hyperthyroidism, and rare cases of other immune-mediated reactions such as pancreatitis, uveitis, demyelination, autoimmune neuropathy, adrenal insufficiency, and facial and abducens nerve paresis.
RX24 Drugs Disclaimer: before buying a Nivolumab on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
